Edward A Stadtmauer
Overview
Explore the profile of Edward A Stadtmauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
183
Citations
9637
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Banerjee R, Fritz A, Akhtar O, Freeman C, Cowan A, Shah N, et al.
Leukemia
. 2025 Feb;
PMID: 39994463
No abstract available.
2.
Ho M, Paruzzo L, Minehart J, Voruganti T, Devi P, Vogl D, et al.
Haematologica
. 2025 Feb;
PMID: 39911104
Not available.
3.
Jadlowsky J, Hexner E, Marshall A, Grupp S, Frey N, Riley J, et al.
Nat Med
. 2025 Jan;
PMID: 39833408
Long-term risks of gene therapy are not fully understood. In this study, we evaluated safety outcomes in 783 patients over more than 2,200 total patient-years of observation from 38 T...
4.
Bhagwat A, Torres L, Shestova O, Shestov M, Mellors P, Fisher H, et al.
Nat Med
. 2024 Sep;
30(12):3697-3708.
PMID: 39333315
Acute myeloid leukemia (AML) is a rapidly progressive malignancy without effective therapies for refractory disease. So far, chimeric antigen receptor (CAR) T cell therapy in AML has not recapitulated the...
5.
Sureda A, Carpenter P, Bacigalupo A, Bhatt V, de la Fuente J, Ho A, et al.
Bone Marrow Transplant
. 2024 Jun;
59(9):1335.
PMID: 38907026
No abstract available.
6.
Hasanali Z, Garfall A, Burzenski L, Shultz L, Tang Y, Kadu S, et al.
JCI Insight
. 2024 May;
9(10).
PMID: 38713510
Multiple myeloma is a largely incurable and life-threatening malignancy of antibody-secreting plasma cells. An effective and widely available animal model that recapitulates human myeloma and related plasma cell disorders is...
7.
Sureda A, Carpenter P, Bacigalupo A, Bhatt V, de la Fuente J, Ho A, et al.
Bone Marrow Transplant
. 2024 Mar;
59(6):832-837.
PMID: 38443706
Despite emergence of novel therapies to treat hematologic malignancies, allogeneic hematopoietic cell transplantation (allo-HCT) remains an essential treatment modality capable of curing these diseases. Allo-HCT has been also shown to...
8.
Brazauskas R, Flynn K, Krishnan A, Landau H, Giralt S, Pasquini M, et al.
Br J Haematol
. 2024 Feb;
204(4):1429-1438.
PMID: 38348544
Autologous haematopoietic cell transplantation (autoHCT) and continuous post-transplant maintenance therapy are the standard of care in transplant-eligible multiple myeloma (MM) patients. We sought to describe symptom burden and identify symptom...
9.
Hasanali Z, Garfall A, Burzenski L, Shultz L, Tang Y, Kadu S, et al.
bioRxiv
. 2024 Feb;
PMID: 38328086
Multiple myeloma is a largely incurable and life-threatening malignancy of antibody-secreting plasma cells. An effective and widely available animal model that recapitulates human myeloma and related plasma cell disorders is...
10.
Ghilardi G, Fraietta J, Gerson J, Van Deerlin V, Morrissette J, Caponetti G, et al.
Nat Med
. 2024 Jan;
30(4):984-989.
PMID: 38266761
We report a T cell lymphoma (TCL) occurring 3 months after anti-CD19 chimeric antigen receptor (CAR) T cell immunotherapy for non-Hodgkin B cell lymphoma. The TCL was diagnosed from a...